Recently, the official website of the National Medical Products Administration (NMPA) announced that tibolone tablets submitted by Changchun GenSci Pharmaceutical Co., Ltd. (hereinafter referred to as GenSci Pharmaceutical) have been approved for marketing for the treatment of low‑estrogen symptoms caused by natural menopause and surgical menopause in women*.

As the first tibolone tablet granted deemed‑to‑have passed the consistency evaluation, the tibolone tablet developed by GenSci Pharmaceutical (Brand Name: Gensaibei®) delivers a new domestic option for clinical Menopausal Hormone Therapy (MHT), and brings more treatment alternatives for menopausal women in China.